UBS Group
KTTA icon

UBS Group’s Pasithea Therapeutics KTTA Stock Holding History

UBS Group’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4K Buy
26,149
+12,886
+97% +$10.8K ﹤0.01% 7958
2025
Q4 		$17.1K Sell
13,263
-5,118
-28% -$4.5K ﹤0.01% 7895
2025
Q3 		$13.5K Sell
18,381
-23,761
-56% -$17.4K ﹤0.01% 8397
2025
Q2 		$30.4K Buy
42,142
+37,805
+872% +$41.3K ﹤0.01% 8151
2025
Q1 		$5.64K Sell
4,337
-8,531
-66% -$15.1K ﹤0.01% 8970
2024
Q4 		$40.5K Buy
12,868
+6,301
+96% +$22.3K ﹤0.01% 7430
2024
Q3 		$35.6K Buy
6,567
+6,529
+17,182% +$32.2K ﹤0.01% 7039
2024
Q2 		$192 Sell
38
-570
-94% -$3.72K ﹤0.01% 9082
2024
Q1 		$4.41K Buy
+608
New +$4.32K ﹤0.01% 7628
2023
Q4 		– Sell
-4
Closed -$40 – 9627
2023
Q3 		$40 Sell
4
-342
-99% -$3.74K ﹤0.01% 9041
2023
Q2 		$3.39K Buy
+346
New +$2.79K ﹤0.01% 7637
2023
Q1 		– Sell
-637
Closed -$8.15K – 9999
2022
Q4 		$8.15K Buy
637
+364
+133% +$7.27K ﹤0.01% 8812
2022
Q3 		$7K Sell
273
-367
-57% -$8.62K ﹤0.01% 8879
2022
Q2 		$13K Buy
+640
New +$13.6K ﹤0.01% 7517
2021
Q4 		– Sell
-165
Closed -$10K – 10491
2021
Q3 		$10K Buy
+165
New +$10K ﹤0.01% 8003

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's KTTA Position: Q1 2026 in Review

UBS Group increased its Pasithea Therapeutics (KTTA) stake by 97% in Q1 2026, buying an estimated $10.8K and bringing the position to 26,149 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7958.

UBS Group first reported a position in KTTA in Q3 2021 and has held it in 15 quarters since. The position peaked at $40.5K in Q4 2024. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • UBS Group held 26,149 shares of Pasithea Therapeutics worth $19.4K as of Q1 2026.
  • UBS Group bought 12,886 Pasithea Therapeutics shares in Q1 2026, an estimated $10.8K.
  • Pasithea Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7958 holding.
  • UBS Group first reported a position in Pasithea Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • UBS Group's Pasithea Therapeutics position peaked at $40.5K in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.